AtriCure (ATRC): Assessing Valuation After First-In-Human PFA/RFA Procedures and Renewed Analyst Optimism [Yahoo! Finance]
Assessing AtriCure's Valuation After a 33.4% Rally in 2025 [Yahoo! Finance]
Analysts See an Over 26% Upside in AtriCure (ATRC) [Yahoo! Finance]
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
AtriCure (NASDAQ:ATRC) had its price target raised by analysts at JPMorgan Chase & Co. from $42.00 to $48.00. They now have an "overweight" rating on the stock.